NEUROENDOCRINE (NE) TUMORS
Clinical trials for NEUROENDOCRINE (NE) TUMORS explained in plain language.
Never miss a new study
Get alerted when new NEUROENDOCRINE (NE) TUMORS trials appear
Sign up with your email to follow new studies for NEUROENDOCRINE (NE) TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare gut tumors? phase 2 trial launches
Disease control Not yet recruitingThis phase 2 trial tests a new drug called AUR103 calcium in 30 people with advanced neuroendocrine tumors that have worsened after at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing. Participants take the drug twice daily unt…
Matched conditions: NEUROENDOCRINE (NE) TUMORS
Phase: PHASE2 • Sponsor: Aurigene Discovery Technologies Limited • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New study aims to reduce harmful side effects in rare cancer patients
Knowledge-focused Not yet recruitingThis study will follow 1,100 people with advanced neuroendocrine tumors (a rare, slow-growing cancer) to see which treatments or treatment sequences cause the fewest long-term side effects. Researchers will track patients for up to 5 years, recording any side effects that last mo…
Matched conditions: NEUROENDOCRINE (NE) TUMORS
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Study to test if patient education improves side effect management for neuroendocrine tumor patients on oral therapy
Knowledge-focused Not yet recruitingThis study will enroll 100 adults with neuroendocrine tumors who are starting oral anti-cancer drugs like everolimus or sunitinib. Researchers want to see if a therapeutic education program—including questionnaires and nurse consultations—helps patients handle side effects and ma…
Matched conditions: NEUROENDOCRINE (NE) TUMORS
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC